Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Rheumatology|April 1, 2026
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
The Journal of Rheumatology|March 3, 2019
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
The Journal of Rheumatology|December 16, 2020
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II StudyMark C Genovese, Alberto Spindler, Akira Sagawa, et al.
Journal of Neuroscience Research|May 28, 2020
Antagonism of peripheral opioid receptors by methylnaltrexone does not prevent morphine tolerance in ratsKim Juhani Blomqvist, Katarzyna Anna Dudek, Hanna Viisanen, et al.
Journal of Biomedical Science|February 2, 2023
Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides populationRajendra Prasad Janapatla, Anna Dudek, Chyi-Liang Chen, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Dermatology and Therapy|March 28, 2025
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability StudyDavid M Pariser, Mark G Lebwohl, Janusz Jaworski, et al.
Advances in Therapy|February 11, 2025
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyMark G Lebwohl, John Y Koo, Janusz Jaworski, et al.
Clinical Drug Investigation|July 12, 2025
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid ArthritisGerd Burmester, Jakub Trefler, Artur Racewicz, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialPhilip Mease, Laura C Coates, Philip S Helliwell, et al.
Pageof 4